601 filings
8-K
GYRE
Gyre Therapeutics Inc
17 Jun 24
Amendments to Articles of Incorporation or Bylaws
4:30pm
S-3
GYRE
Gyre Therapeutics Inc
Shelf registration
30 May 24
4:06pm
8-K
GYRE
Gyre Therapeutics Inc
30 May 24
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
4:05pm
S-3
GYRE
Gyre Therapeutics Inc
Shelf registration
30 May 24
4:02pm
10-Q
2024 Q1
GYRE
Gyre Therapeutics Inc
Quarterly report
13 May 24
4:07pm
8-K
bjqnbb7qyke
9 May 24
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:05pm
8-K
e2m1r3fkc
8 May 24
Regulation FD Disclosure
8:00am
ARS
xfi zdykymhjx4
29 Apr 24
Annual report to shareholders
8:49am
DEFA14A
gvi34ko4 os93t91
29 Apr 24
Additional proxy soliciting materials
8:48am
S-8
cud ptymaq1fq
27 Mar 24
Registration of securities for employees
9:00pm
8-K
k2squyvrq0k
26 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:03pm
8-K
rq6c4o4
25 Mar 24
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
9:55pm
8-K
x6wb vpa82y6tr5bfv
21 Mar 24
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
7:15am
8-K
w5xq5uz2rvlmh g8qhyw
14 Feb 24
Results of Operations and Financial Condition
5:16pm
8-K/A
9naxuu pq
19 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K/A
mvrvsio8s
12 Jan 24
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
v8gxd2
15 Dec 23
Departure of Directors or Certain Officers
4:21pm